Health

Caliway's CBL-514 Achieved Better Efficacy than Liposuction, Reducing over 300mL of Subcutaneous Fat on Average in CBL-0202 Study

- CBL-0202 Phase 2 study results met all the primary and secondary endpoints. - 69.9% and 60.9% of participants lost at least 150mL and 200mL of abdominal subcutaneous fat in the treated area after CBL-514 treatment. - Compared with placebo, an average of 312.1mL of subcutaneous fat was reduced in...

2023-10-02 21:00 1211

Cambrex Completes $38 Million Capacity Expansion in High Point, North Carolina

EAST RUTHERFORD, N.J, Oct. 2, 2023 /PRNewswire/ -- Cambrex today announced the completion of its$38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility inHigh Point, North Carolina. This expansion doubles the facility's manufacturing capa...

2023-10-02 20:51 1738

Advancing Cancer Treatment: Leo Cancer Care and THERYQ Collaborate on Innovative FLASHDEEP Patient Positioning

PEYNIER, France, Oct. 2, 2023 /PRNewswire/ -- The collaboration between Leo Cancer Care and THERYQ brings together the extensive expertise of both organizations to create an integrated solution that promises to revolutionize the treatment of deep-seated tumors. Leveraging cutting-edge technology ...

2023-10-02 20:31 1550

Flat Medical Secures Series C Funding Led by Taiwania Capital, Poised for Global Market Expansion

TAIPEI, Oct. 2, 2023 /PRNewswire/ -- Flat Medical, the leading medtech company specializing in innovative safety solutions for anesthesia, pain medicine, critical care and emergency medicine, is thrilled to announce the successful closing of its Series C funding round. The round was led by renown...

2023-10-02 20:30 1534

MedAlliance Acquired by Cordis for up to USD 1.135 Billion

GENEVA, Switzerland, Oct. 2, 2023 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has been acquired by Cordis for a 2022 investment of$35M and a 2023 upfront closing payment of $200M, together with regulatory achievement milestones of up to$125M and commercial milestones of up ...

2023-10-02 20:27 7673

ZEISS and Boehringer Ingelheim join forces to develop early detection of eye diseases and prevent vision loss

JENA, Deutschland and INGELHEIM, Deutschland, Oct. 2, 2023 /PRNewswire/ -- ZEISS Medical Technology and Boehringer Ingelheim announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vis...

2023-10-02 20:00 1455

SIBIONICS to Make Debut at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

SHENZHEN, China, Oct. 2, 2023 /PRNewswire/ -- The 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to take place from October 2nd to 6th, 2023, in Hamburg, Germany. Making its debut at this prestigious event, Shenzhen Sibionics Technology Co., Ltd. (hereinaft...

2023-10-02 16:24 2458

China Review Studio and Chinese Red Cross Foundation Release "Generation Vax" Documentary for Broadcast Internationally

The documentary outlines China's contribution to vaccine science, research, and production since the COVID-19 pandemic and includes a call for science and infectious disease research to be borderless. BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese R...

2023-10-02 15:00 2201

MedAlliance Acquired by Cordis for USD 1.135 Billion

GENEVA, Oct. 2, 2023 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has been acquired by Cordis for a 2022 investment of$35M and a 2023 upfront closing payment of$200M, together with regulatory achievement milestones of up to$125M and commercial milestones of up to $775M throu...

2023-10-02 11:44 2327

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

WUXI, China, Oct. 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner, Amicus Therapeutics ("Amicus") (Nasdaq: FOLD), on receiving U.S. FDA's approval for Pombili...

2023-10-02 08:30 1341

Health In Tech, AMPS, and Drexi Host a Special Happy Hour Event at SIIA Conference

STUART, Fla., Sept. 29, 2023 /PRNewswire/ -- Health In Tech, an industry-leading insurtech company that delivers disruptive innovation and re-imagines self-funded health plans, is thrilled to announce a collaborative Happy Hour event with industry leaders AMPS and Drexi. This event, scheduled du...

2023-09-29 22:18 2628

Akeso and RemeGen Collaborate on Clinical Study Exploring the Potential of PD-1/CTLA-4 Bispecific Antibody with HER-2 ADC Combination Therapy in Gastric Cancer

HONG KONG, Sept. 29, 2023 /PRNewswire/ -- On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/09995.HK) to advance the development of Akeso's globally first PD-1/CTLA-4 bispecific antibody, cadonilimab ...

2023-09-29 20:00 2829

Rimegepant is Now Available in Hong Kong, the First Market in Asia, for Migraine Management

HONG KONG, Sept. 29, 2023 /PRNewswire/ -- Pfizer announced the availability of Rimegepant inHong Kong, the first market in Asia, a calcitonin gene-related peptide (CGRP) receptor antagonist for migraine management.[1],[2] There are approximately 12.5% of people living with migraine inHong Kong[3]...

2023-09-29 17:03 2743

#UseHeart movement rallies for change as heart disease continues to claim most lives

GENEVA, Sept. 29, 2023 /PRNewswire/ -- This World Heart Day, the World Heart Federation (WHF) is urging all sectors and citizens to join forces and take down cardiovascular disease (CVD) from its "number one killer" position.

2023-09-29 16:04 2198

Bowtie designed insurance plan for individuals aged 50+ before retirement

HONG KONG, Sept. 29, 2023 /PRNewswire/ -- As individuals in their 50s approach retirement, they not only face the loss of a stable monthly income but also the termination of group medical insurance. Considering the increased risk of illness associated with aging, having adequate coverage becomes ...

2023-09-29 15:40 3323

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep. BNC210 was well-tolerated with a safety prof...

2023-09-29 12:13 2132

Cutting-edge cancer imaging tool allows doctors to efficiently adapt radiotherapy treatment

First patient treated on radiotherapy system equipped with HyperSight imaging solution at Icon Cancer Centre MELBOURNE, Australia, Sept. 29, 2023 /PRNewswire/ -- An innovative technology that captures high-quality images of a tumor in six seconds is being used to guide cancer treatments for pati...

2023-09-29 10:06 1894

Academic Conference on "Research on Female Reproductive Health in International Perspective" Successfully Concluded

HONG KONG, Sept. 29, 2023 /PRNewswire/ -- On September 22nd, the academic conference on "Female Reproductive Health Research in International Perspective", organized by Hong Kong Research Institute of Modern Chinese Medicine for Reproductive Anti-aging(HKMCMRA), was successfully concluded in Hong...

2023-09-29 09:00 2931

Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

HANGZHOU and SHAOXING, China, Sept. 29, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces positive interim data from the Phase IIb expansion cohort (the "Expansion Cohort") of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) for functional cure of ch...

2023-09-29 08:10 2531

Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

82.4% of patients without prior CAR-T achieving Complete Response (CR) or better ROCKVILLE, Md. and SUZHOU, China, Sept. 29, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-qualit...

2023-09-29 08:00 2639
1 ... 158159160161162163164 ... 847